Full Answer
Is Atai life sciences'stock a buy or sell?
Only 7.63% of the stock of Atai Life Sciences is held by institutions. Earnings for Atai Life Sciences are expected to decrease in the coming year, from ($0.80) to ($1.11) per share. Is Atai Life Sciences a buy right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year.
Where can I buy Atai shares?
Shares of ATAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What is atai impact?
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health App... atai Impact is committed to advancing education, expanding access and supporting the wider ecosystem of mental health care atai Impact is committed to advancing education, expanding access and supportin...
What's going on with Atai life sciences'pcn-101 drug candidate?
Perception Neuroscience, an Atai Life Sciences (NASDAQ:ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate. The study will evaluate the safety and efficacy of a p...
See more
Is Atai life sciences publicly traded?
Atai was founded in 2018 and went public in June 2021, raising net proceeds of $231.6 million at $15 per share. Its stock trades around $3.75 a share, translating to a market cap of approximately $650 million.
Is Atai Life Sciences a good stock to buy?
Out of 8 analysts, 5 (62.5%) are recommending ATAI as a Strong Buy, 2 (25%) are recommending ATAI as a Buy, 1 (12.5%) are recommending ATAI as a Hold, 0 (0%) are recommending ATAI as a Sell, and 0 (0%) are recommending ATAI as a Strong Sell.
Will ATAI stock go up?
The 10 analysts offering 12-month price forecasts for ATAI Life Sciences NV have a median target of 22.00, with a high estimate of 50.00 and a low estimate of 6.60. The median estimate represents a +486.67% increase from the last price of 3.75.
Does ATAI pay a dividend?
Atai Life Sciences Nv (NASDAQ: ATAI) does not pay a dividend.
Should I buy CMPS stock?
Out of 2 analysts, 0 (0%) are recommending CMPS as a Strong Buy, 2 (100%) are recommending CMPS as a Buy, 0 (0%) are recommending CMPS as a Hold, 0 (0%) are recommending CMPS as a Sell, and 0 (0%) are recommending CMPS as a Strong Sell. What is CMPS's earnings growth forecast for 2022-2024?
Should I buy or sell Atai Life Sciences stock right now?
13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last twelve months. There are currentl...
What is Atai Life Sciences' stock price forecast for 2022?
13 Wall Street analysts have issued 1 year target prices for Atai Life Sciences' stock. Their forecasts range from $9.00 to $50.00. On average, the...
How has Atai Life Sciences' stock performed in 2022?
Atai Life Sciences' stock was trading at $7.63 on January 1st, 2022. Since then, ATAI stock has decreased by 57.9% and is now trading at $3.21. Vi...
When is Atai Life Sciences' next earnings date?
Atai Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022. View our earnings forecast for At...
How were Atai Life Sciences' earnings last quarter?
Atai Life Sciences (NASDAQ:ATAI) released its earnings results on Monday, May, 16th. The company reported ($0.24) earnings per share (EPS) for the...
Who are Atai Life Sciences' key executives?
Atai Life Sciences' management team includes the following people: Mr. Florian Brand , Co-Founder, MD & CEO (Age 35, Pay $405.02k) Dr. Srinivas...
Who are some of Atai Life Sciences' key competitors?
Some companies that are related to Atai Life Sciences include EQRx (EQRX) , PTC Therapeutics (PTCT) , Ironwood Pharmaceuticals (IRWD) , Schrödi...
What other stocks do shareholders of Atai Life Sciences own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG) ,...
When did Atai Life Sciences IPO?
(ATAI) raised $200 million in an initial public offering on Friday, June 18th 2021. The company issued 14,300,000 shares at $13.00-$15.00 per share...
What is Atai Life Sciences?
Atai Life Sciences N.V. focuses on operating as a holding company for ATAI Life Sciences AG that operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that are focused on multiple mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a GABA/nicotinic modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01 is a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
When does the lock up period end for Atai Life Sciences?
Atai Life Sciences' lock-up period expires on Wednesday, December 15th. Atai Life Sciences had issued 15,000,000 shares in its IPO on June 18th. The total size of the offering was $225,000,000 based on an initial share price of $15.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Is Atai Life Sciences a buy?
Atai Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.
Does Atai Life Sciences pay dividends?
Atai Life Sciences does not currently pay a dividend.
